These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 18676566

  • 1. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM, Friedman RA, Knilans TK, Black Box Working Group, Section on Cardiology and Cardiac Surgery.
    Pediatrics; 2008 Aug; 122(2):451-3. PubMed ID: 18676566
    [No Abstract] [Full Text] [Related]

  • 2. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
    Newcorn JH, Donnelly C.
    Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385
    [No Abstract] [Full Text] [Related]

  • 3. Stimulants for kids with ADHD--how to proceed safely.
    Ken Mehta S, Jacobs I.
    J Fam Pract; 2014 Feb; 63(2):E1-5. PubMed ID: 24527478
    [Abstract] [Full Text] [Related]

  • 4. Stimulants and sudden death: what is a physician to do?
    Wilens TE, Prince JB, Spencer TJ, Biederman J.
    Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
    [Abstract] [Full Text] [Related]

  • 5. [Treatment with central nervous system stimulants. Practical guidelines].
    Hvolby A, Jørgensen JI.
    Ugeskr Laeger; 2004 Jan 12; 166(3):144-8. PubMed ID: 14870640
    [No Abstract] [Full Text] [Related]

  • 6. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A.
    Pediatrics; 2007 Dec 12; 120(6):e1494-501. PubMed ID: 18055666
    [Abstract] [Full Text] [Related]

  • 7. Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.
    Power TJ, Mautone JA, Manz PH, Frye L, Blum NJ.
    Pediatrics; 2008 Jan 12; 121(1):e65-72. PubMed ID: 18166546
    [Abstract] [Full Text] [Related]

  • 8. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
    Knight M.
    Pediatrics; 2007 Jan 12; 119(1):154-5. PubMed ID: 17200281
    [No Abstract] [Full Text] [Related]

  • 9. Cardiovascular risk screening before starting stimulant medications and prescribing practices of canadian physicians: impact of the Health Canada advisory.
    Conway J, Wong KK, O'Connell C, Warren AE.
    Pediatrics; 2008 Oct 12; 122(4):e828-34. PubMed ID: 18829780
    [Abstract] [Full Text] [Related]

  • 10. Medications for attention deficit hyperactivity disorder: cardiovascular concerns.
    Wooltorton E.
    CMAJ; 2006 Jul 04; 175(1):29. PubMed ID: 16772535
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacotherapy in ADHD. Guidelines for prescribing stimulant medications in young children.
    August GJ, Realmuto GM.
    Minn Med; 2000 Jun 04; 83(6):45-6. PubMed ID: 10881573
    [No Abstract] [Full Text] [Related]

  • 13. Safety of stimulant treatment in attention deficit hyperactivity disorder: part II.
    Merkel RL.
    Expert Opin Drug Saf; 2010 Nov 04; 9(6):917-35. PubMed ID: 20615078
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Attitude to questionable cadiac risks in stimulant administration].
    Fegert JM, Hebebrand J, Kommission Entwicklungspsychopharmakologie der drei Fachgesellschaften.
    Z Kinder Jugendpsychiatr Psychother; 2006 Jul 04; 34(4):295-7. PubMed ID: 16927572
    [No Abstract] [Full Text] [Related]

  • 16. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.
    Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL, American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee, American Heart Association Council on Cardiovascular Nursing.
    Circulation; 2008 May 06; 117(18):2407-23. PubMed ID: 18427125
    [No Abstract] [Full Text] [Related]

  • 17. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN, Wilde AA.
    Ned Tijdschr Geneeskd; 2006 Aug 05; 150(31):1713-4. PubMed ID: 16924941
    [Abstract] [Full Text] [Related]

  • 18. ADHD drugs and cardiovascular risk.
    Rappley MD, Moore JW, Dokken D.
    N Engl J Med; 2006 May 25; 354(21):2296-8; author reply 2296-8. PubMed ID: 16729375
    [No Abstract] [Full Text] [Related]

  • 19. Growth in stimulant-naive children with attention-deficit/hyperactivity disorder using cross-sectional and longitudinal approaches.
    Hanć T, Cieślik J.
    Pediatrics; 2008 Apr 25; 121(4):e967-74. PubMed ID: 18381524
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE.
    J Am Acad Child Adolesc Psychiatry; 2011 Oct 25; 50(10):978-90. PubMed ID: 21961773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.